Studienzentrum Onkologie Ravensburg GmbH

At Studienzentrum Onkologie Ravensburg GmbH, a major share of the clinical trial portfolio focuses on neoplasms, with studies spanning breast cancer, lung cancer, lymphoma, and gastrointestinal cancers. The research is centered on testing new treatment options, comparing them with current standards, and improving outcomes for people with advanced or hard-to-treat cancers.

• Advanced and metastatic breast cancer, especially hormone receptor-positive and HER2-negative disease
• Non-small cell lung cancer and other advanced lung tumors
• Hodgkin lymphoma and treatment strategies aimed at better disease control
• Esophagogastric, gastric, and colorectal cancers with a focus on treatment effectiveness

These trials are designed to evaluate new therapies, refine established cancer care, and explore ways to improve survival, symptom control, and long-term disease management.

The site also conducts strong research in digestive system diseases, particularly cancers of the colon, rectum, stomach, and gastroesophageal junction. The studies aim to improve treatment planning, assess the value of additional therapy after surgery, and compare approaches for both localized and metastatic disease.

• Colon cancer and rectal cancer, including stage II and locally advanced disease
• Metastatic colorectal cancer and strategies to improve disease control after initial treatment
• Gastric cancer and gastroesophageal junction adenocarcinoma
• Research on treatment sequencing, follow-up care, and reducing recurrence risk

This work supports better decisions about surgery-related care, additional systemic therapy, and the most effective way to manage advanced gastrointestinal cancers.

Several trials at the Ravensburg oncology center are dedicated to breast cancer, especially estrogen receptor-positive and HER2-negative disease. The research includes both early-stage and metastatic settings, with attention to finding more effective and better-tolerated treatment options.

• Localized, locally advanced, and metastatic breast cancer
• Hormone receptor-positive disease requiring improved systemic treatment choices
• Studies comparing new endocrine-based approaches with current standards
• Trials aimed at improving outcomes while reducing treatment burden

This research reflects a broad effort to refine care for patients with breast cancer, from earlier disease to more advanced stages.

The clinical trial program includes important work in lung cancer, especially non-small cell lung cancer with advanced or metastatic disease. These studies are evaluating new treatment combinations and comparing them with established therapies to improve disease control and survival.

• Advanced non-small cell lung cancer with high PD-L1 expression
• Metastatic lung cancer requiring more effective treatment options
• Research focused on immunotherapy-based and targeted treatment strategies
• Studies assessing whether newer approaches can outperform current standards

The work at Studienzentrum Onkologie Ravensburg GmbH contributes to ongoing efforts to improve care for patients with difficult-to-treat lung tumors.

A notable part of the research activity addresses gastrointestinal cancers, including stomach cancer, gastroesophageal junction adenocarcinoma, and metastatic colorectal cancer. The trials are exploring better ways to use surgery, chemotherapy, and follow-up treatment to reduce recurrence and extend disease control.

• Gastroesophageal junction adenocarcinoma in resectable and advanced settings
• Stomach cancer after prior treatment
• Metastatic colorectal cancer with strategies to improve long-term outcomes
• Comparisons of treatment approaches to identify more effective care pathways

These studies are aimed at improving treatment effectiveness across several digestive tract cancers that remain challenging to manage.